We here demonstrate the potency of commonly prescribed drugs in the management of CKD comorbidities (ACEIs, ARBs, statins and diuretics) [24,27,57,58] to inhibit basolateral OAT1-mediated uptake of fluorescein at clinically relevant concentrations. Here, SLC22A6 is linked to chronic kidney disease.